CGEN
Another slice off the top
Compugen’s CEO, Eran Ophir, sold 5,000 shares on April 14 at $2.90 apiece, according to the filing cited in the article. That follows a separate sale of 5,625 shares on April 1 at $2.21, so this wasn’t exactly a one-off “oops, forgot I owned stock” moment.
Why you should care
The sales happened under a pre-arranged Rule 10b5-1 plan, which is corporate-speak for “this was scheduled ahead of time, not a panic button.” Still, the moves cut Ophir’s direct stake to 11,375 shares, down about 30.5%, and investors tend to notice when the person driving the ship keeps lightening the load.
The fine print matters
Insider sales can mean a bunch of things: tax planning, portfolio diversification, or just following a preset trading plan. But when a CEO sells twice in the same month, the market usually leans in a little closer and asks, “Okay, but what does management know that we don’t?”
Big picture
This isn’t a business-changing event by itself, but it can nudge sentiment around a small-cap biotech name where confidence is already doing most of the heavy lifting. If you own the stock, it’s worth keeping on your radar — not because the sale screams trouble, but because it’s the kind of thing that can quietly color how investors read the next update.